Jason M. Broderick

Published data show the PD-1 inhibitor induced strong antitumor activity in patients with both advanced clear cell renal cell carcinoma (ccRCC) and advanced non-ccRCC.

A 4-week hypofractionated radiotherapy course was associated with a lower risk of bladder cancer recurrence compared with a 6.5-week standard treatment course.

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.

In a phase 3 trial, biochemical failure-free survival and disease-free survival were improved with prophylactic whole-pelvic radiotherapy versus prostate-only radiotherapy.

The rates of mental healthcare use were significantly higher for patients versus healthy controls during diagnosis, treatment, and long-term survivorship.

Abiraterone acetate, enzalutamide, and apalutamide are highlighted among the standards of care for initial treatment.

The risks of erectile dysfunction or rectourethral fistula post-cryosurgery were also not increased by prior surgical interventional therapy for benign prostatic hyperplasia.

Stereotactic body radiotherapy produced similar efficacy without added toxicity compared with standard radiation in men with advanced prostate cancer.

Twelve percent of patients with negative results on conventional imaging had lesion localization on 18F-fluciclovine PET.

The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses.

The PD-L1 inhibitor was approved based on data from the phase 3 JAVELIN Bladder 100 study.

The approval is based on data from the phase 3 CheckMate-9ER trial.

The GnRH receptor antagonist was approved by the FDA in December 2020 for the treatment of patients with advanced prostate cancer.

The boost improved biochemical disease-free survival without negatively affecting safety and quality of life.

The trend in prostate cancer aligns with an overall decline in cancer-related suicide across all tumor types.

The study contradicts the findings from an Italian study published in 2020.

The investigational padeliporfin ImPACT platform involves the intravenous delivery of the photosensitive drug padeliporfin, which is then activated by a non-thermal light delivery system.

Higher medical mistrust and concerns about masculinity likely contribute to the increased decision regret.

The integrated radiomic-clinicopathologic nomogram (RadClip) was a better prognosticator of biochemical recurrence-free survival and adverse pathology than other standard tools.

The collaboration will focus on the novel combinatorial intravesical immunotherapy UGN-302 as a potential treatment for patients with high-grade non-muscle invasive bladder cancer.

Compared with single men, those in this age group who were married/partnered had 65% lower odds of having ED.

Among patients with 6 years’ follow-up, no differences were observed between ultra-hypofractionation and conventional fractionation in the rates of clinically relevant deterioration in overall urinary bother, overall bowel bother, overall sexual bother, or global health/QoL.

Disease stage and adverse features were the main predictors of relapses and survival after robot-assisted radical cystectomy.

A large review showed that cancer specific survival was improved in overweight and obese patients with renal cell carcinoma compared with patients with normal BMI.

The approval was based on findings from the phase 3 JAVELIN Bladder 100 study.

The investigators drew specific attention to the impact of their findings on prostate ablation therapy.

In the ARAMIS trial, darolutamide reduced the risk of death by 31% compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

The goal of the study is to establish real-world efficacy evidence of using the Soltive Laser System for laser lithotripsy.

The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.

The combination of eganelisib and nivolumab demonstrated promising activity and was well tolerated in a phase 2 trial of patients with advanced urothelial cancer.